Jennifer Lachey - 11 Jun 2021 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Signature
/s/ Keith Regnante, Attorney-in-Fact
Issuer symbol
KROS
Transactions as of
11 Jun 2021
Net transactions value
-$134,292
Form type
4
Filing time
15 Jun 2021, 17:02:40 UTC
Previous filing
13 May 2021
Next filing
25 Jun 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Options Exercise $795 +2,650 +3.4% $0.3000* 80,557 11 Jun 2021 Direct
transaction KROS Common Stock Sale $77,217 -1,533 -1.9% $50.37 79,024 11 Jun 2021 Direct F1, F2
transaction KROS Common Stock Sale $46,454 -898 -1.1% $51.73 78,126 11 Jun 2021 Direct F1, F3
transaction KROS Common Stock Sale $11,416 -219 -0.28% $52.13 77,907 11 Jun 2021 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -2,650 -2% $0.000000 129,705 11 Jun 2021 Common Stock 2,650 $0.3000 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.96 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4).
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.065 to $52.05 inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.12 to $52.53 inclusive.
F5 Immediately exercisable.